Loading
CAR-T is not a prescription but a manufacturing process. Cells are collected from the patient, sent away to be engineered, and returned three to five weeks later. What happens during that wait decides whether the treatment is given at all.
The steps, in order. Referral to a CAR-T centre as soon as relapse is suspected, because the pathway is long and a person who deteriorates during it becomes ineligible. Eligibility assessment: performance status, cardiac and renal function, absence of active central nervous system disease in some products, control of infection. Leukapheresis to collect T cells, usually one four-hour session; lymphocyte count and recent bendamustine or prolonged steroid exposure both reduce the quality of the collected cells, which is a reason to refer before the last line rather than after it. Manufacture and release testing, typically three to five weeks. Bridging therapy while waiting, to hold the disease without harming the cells: steroids, radiotherapy to a dominant mass, polatuzumab-based or gemcitabine-based chemotherapy, or a bispecific antibody. Lymphodepletion with fludarabine and cyclophosphamide over three days. Infusion, then inpatient or close outpatient monitoring for two to four weeks for cytokine release syndrome and neurotoxicity. Follow-up for cytopenias, hypogammaglobulinaemia and infection for months to years.
What goes wrong. In ZUMA-7 and TRANSFORM the second-line CAR-T arms beat salvage chemotherapy with transplant partly because far more patients actually received the assigned treatment. In BELINDA, which was negative, a longer manufacture and permitted bridging with further chemotherapy blurred the comparison. Time is the variable that the trials keep pointing at.
In England CAR-T is delivered at a small number of commissioned centres and requires national panel approval; the practical consequence is travel and a carer for several weeks. In the United States it is delivered at accredited centres, with outpatient administration increasingly common for lisocabtagene maraleucel. Neither system makes it quick.
Showing the molecule this term concerns: Fludarabine.
Shares JULIET, TRANSCEND NHL 001, Cytokine release syndrome and ICANS: grading and management, Axicabtagene ciloleucel.
Shares Treatment at the local hospital or at a cell-therapy centre far from home, Transplant or CAR-T at second line in diffuse large B-cell lymphoma, Brexucabtagene autoleucel, ELARA.
Shares TRANSFORM, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, TRANSCEND NHL 001, Lisocabtagene maraleucel.
Shares BELINDA, TRANSFORM, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma.
Shares BELINDA, TRANSFORM, Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma, Lisocabtagene maraleucel.
Shares ELARA, POD24: progression of follicular lymphoma within two years, and why it changes the plan, Cytokine release syndrome and ICANS: grading and management, Axicabtagene ciloleucel.
Shares Lymphodepletion before CAR-T, ELARA, Axicabtagene ciloleucel, Fludarabine.
Shares Lymphodepletion before CAR-T, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, JULIET, Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma.